MTZ Clinical Research Sp. z o.o. is the leading Polish company specialized in conducting early phases clinical trials, bioequivalence and bioavailability studies. The company has been operating since 2002, conducting studies for European and American pharmaceutical and biopharmaceutical companies and CROs (Contract Research Organizations). MTZ conducts the following type of studies: - Phase I/II healthy & patients, various indications - Special populations - Proof-of-Concept - Bioequivalence - Bioavailability - Food effect - PK/PD studies - Biosimilars - Therapeutic equivalence - Tobacco risk evaluation & smoking-cessation studies. The majority of studies is conducted at own clinical research site, designed for up to 30 subjects. In addition to that, the company conducts single and multicentre trials (Phase II) at specialized clinics across Poland. The clinical research site is also used as specialized site in Phase III studies. Since August 2009 MTZ Clinical Research holds ISO 9001:2008 Certificate from DAS CERTIFICATION Ltd. accredited by UKAS: ■Conduct of contracted clinical trials ■Operation of MTZ Clinical Research Site ■Medical services in the field of laboratory diagnostics in the Research Centre MTZ has conducted over 150research projects with over 6000 participating healthy subjects and patients. Subjects are recruited from our own registered database of volunteers. Over 10 000 healthy volunteers and patients are registered there, both smokers and non-smokers at the age range of 18-75 years. The company head office and clinical research site are located in the "Ochota" Campus at Institute of Experimental and Clinical Medicine of the Polish Academy of Sciences near Public Central Teaching Hospital and Warsaw Medical University (Warsaw, Poland).
